Filtered By:
Source: American Heart Journal
Condition: Heart Attack
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 253 results found since Jan 2013.
Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial
Conclusions Patients with prior stroke are at higher risk for recurrent cardiovascular events post-ACS and had a differential risk/benefit profile with oral anticoagulation.
Source: American Heart Journal - October 25, 2017 Category: Cardiology Source Type: research
National trends in stroke after acute myocardial infarction among Medicare patients in the United States: 1999 to 2010
Conclusions From 1999 to 2010, the 1-year risk for ischemic stroke after AMI declined, whereas the risk of hemorrhagic stroke remained unchanged. However, 30-day and 1-year mortality continued to be high.
Source: American Heart Journal - December 9, 2014 Category: Cardiology Source Type: research
Impact of standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke (MonDAFIS) – Rationale and design of a prospective randomized multicenter study
Conclusion MonDAFIS will be the largest study to date to evaluate whether a prolonged and systematic ECG monitoring during the initial in hospital stay has an impact on secondary stroke prevention. In addition, prognosis as well as adherence to medication up to two years after the index stroke will be analyzed. The primary results of the MonDAFIS study may have the potential to change the current guidelines recommendations regarding ECG work-up after ischemic stroke.
Source: American Heart Journal - October 22, 2015 Category: Cardiology Source Type: research
Association of the ankle-brachial index with history of myocardial infarction and stroke
Background: Ankle-brachial index (ABI) testing is a simple, noninvasive method to diagnose peripheral artery disease (PAD) and is associated with all-cause mortality. The association of ABI levels and myocardial infarction (MI) and stroke is less certain. We sought to further characterize the association between ABI levels and history of MI and stroke.Methods: Using data from the Life Line Screening program, 3.6 million self-referred participants from 2003 to 2008 completed a medical questionnaire and had bilateral ABIs performed. Logistic regression was used to estimate the association between ABI cutoff points (ABI 1.40)...
Source: American Heart Journal - January 6, 2014 Category: Cardiology Authors: W. Schuyler Jones, Manesh R. Patel, Caron B. Rockman, Yu Guo, Mark Adelman, Thomas Riles, Jeffrey S. Berger Tags: Peripheral Vascular Disease Source Type: research
Role of diabetes and insulin use in the risk of stroke and acute myocardial infarction in patients with atrial fibrillation: A Medicare analysis
ConclusionThere is an incremental risk of ischemic stroke and MI from non-diabetics to non-insulin diabetics with the highest risk in insulin users. Protective effect of anticoagulation is attenuated with insulin use.
Source: American Heart Journal - May 11, 2019 Category: Cardiology Source Type: research
Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: Rationale and design of the Insulin Resistance Intervention after Stroke Trial
Publication date: December 2014 Source:American Heart Journal, Volume 168, Issue 6 Author(s): Catherine M. Viscoli , Lawrence M. Brass , Antonio Carolei , Robin Conwit , Gary A. Ford , Karen L. Furie , Mark Gorman , Peter D. Guarino , Silvio E. Inzucchi , Anne M. Lovejoy , Mark W. Parsons , Peter N. Peduzzi , Peter A. Ringleb , Gregory G. Schwartz , J. David Spence , David Tanne , Lawrence H. Young , Walter N. Kernan Background Recurrent vascular events remain a major source of morbidity and mortality after stroke or transient ischemic attack (TIA). The IRIS Trial is evaluating an approach to secondary prevention based o...
Source: American Heart Journal - November 25, 2014 Category: Cardiology Source Type: research
Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: GLORIA-AF Registry
Conclusions These global data confirm the sustained safety and effectiveness of dabigatran over 2years of follow-up, consistent with the results from clinical trials as well as contemporary real-world studies. WHAT IS KNOWN • Non- vitamin K antagonist (VKA) anticoagulants (NOACs) are the preferred therapy for prevention of ischemic stroke based on phase 3 trials, but there is insufficient information on their efficacy and safety in daily practice, based on prospectively collected data WHAT IS NEW • This study shows that in non-valvular AF patient population, with up to 2years of follow-up, the use of dabigatran led to ...
Source: American Heart Journal - September 1, 2017 Category: Cardiology Source Type: research
Improving outcomes in patients with atrial fibrillation: Rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial
Conclusion: EAST will determine whether rhythm control therapy, when applied early after the initial diagnosis of AF, can prevent cardiovascular complications associated with AF.
Source: American Heart Journal - August 1, 2013 Category: Cardiology Authors: Paulus Kirchhof, Günter Breithardt, A. John Camm, Harry J. Crijns, Karl-Heinz Kuck, Panos Vardas, Karl Wegscheider Tags: Trial Design Source Type: research
Diabetes, diabetes severity and coronary heart disease risk equivalence REasons for Geographic and Racial Differences in Stroke (REGARDS)
Conclusions Participants with diabetes had lower risk of CHD events than those with prevalent CHD. However, participants with severe diabetes had similar risk as those with prevalent CHD. Diabetes severity may need consideration when deciding whether diabetes is a CHD risk equivalent.
Source: American Heart Journal - August 11, 2016 Category: Cardiology Source Type: research
Diabetes, diabetes severity, and coronary heart disease risk equivalence: REasons for Geographic and Racial Differences in Stroke (REGARDS)
Conclusions Participants with diabetes had lower risk of CHD events than did those with prevalent CHD. However, participants with severe diabetes had similar risk to those with prevalent CHD. Diabetes severity may need consideration when deciding whether diabetes is a CHD risk equivalent.
Source: American Heart Journal - September 5, 2016 Category: Cardiology Source Type: research
Differential Occurrence, Profile, and Impact of First Recurrent Cardiovascular Events After an Acute Coronary Syndrome
Conclusions Approximately 9% of patients experienced a first cardiovascular event in the post-ACS setting during a median follow-up of 1year. While the profile and prognostic implications of stroke versus MI as the first nonfatal event differ substantially, approximately one-third of these patients experienced a second event, typically soon after the first event. These findings have implications for improving post-ACS care and influencing the design of future cardiovascular trials.
Source: American Heart Journal - February 20, 2017 Category: Cardiology Source Type: research
Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients
Conclusions Among older patients with AF and CAD, overall warfarin use was low. Patients ≥80 years old at highest stroke risk received warfarin in similar proportions to the overall cohort. Further investigation into optimizing antithrombotic strategies in this population is warranted.
Source: American Heart Journal - October 20, 2014 Category: Cardiology Source Type: research
Efficacy and Safety of Rivaroxaban in Patients with Diabetes and Nonvalvular Atrial Fibrillation: The ROCKET AF Trial
Conclusions and Relevance The relative efficacy and safety of rivaroxaban vs. warfarin was similar in patients with and without DM, supporting use of rivaroxaban as an alternative to warfarin in diabetic patients with AF.
Source: American Heart Journal - July 30, 2015 Category: Cardiology Source Type: research
